Latest Regulatory Development News

Silver Mines Limited reports steady progress on its flagship Bowdens Silver Project and initiates diamond drilling at the Elsienora Gold Project, while navigating complex regulatory hurdles in New South Wales.

Actinogen Medical advances its XanaMIA phase 2b/3 Alzheimer’s trial with faster patient enrolment and expands clinical sites, while achieving a pivotal FDA meeting outcome for its depression program. The company maintains a strong cash position, supporting ongoing development and commercialization efforts.

Imugene Limited reports encouraging Phase 1b results for azer-cel in lymphoma, secures FDA Fast Track status, and strengthens patent portfolio while raising A$20 million to fuel ongoing immuno-oncology programs.

Piche Resources has extended its Cerro Chacon gold-silver mineralised corridor to 14km and identified multiple high-grade uranium zones at Sierra Cuadrada, setting the stage for an 8,000m drilling campaign in 2Q 2025.

Santos Limited’s 2024 Annual Report reveals a 5% decline in production and a 9% drop in sales revenue, yet highlights significant progress in carbon capture and storage projects and emissions reduction targets.

Adriatic Metals has announced a two-tranche institutional placement to raise A$80 million, aiming to fast-track the expansion of its Vares Processing Plant and strengthen its balance sheet ahead of commercial production.

HUB24 Limited has reported robust growth in its half-year results to December 2024, with revenue climbing 25% and underlying net profit after tax soaring 40%. The company also announced a 30% increase in its fully franked interim dividend, underscoring confidence in its ongoing momentum.

Aurizon Holdings posted a 3% revenue increase to $2.02 billion for 1HFY2025 but saw EBITDA dip 4% to $814 million, reflecting operational headwinds across key segments. The company declared a 9.2 cents per share interim dividend, signaling cautious optimism despite margin pressures.

Fiducian Group has delivered a robust FY2025 half-year performance, marked by strong net inflows and a 23% rise in funds under administration, underpinning solid revenue growth and a confident dividend outlook.

Recce Pharmaceuticals has temporarily paused trading of its securities, signaling a potentially significant development pending further disclosure.

Origin Energy reported a robust half-year result for December 2024, with revenue up 10% and profit rising 2%, while accelerating investments in battery storage and renewables.

Infini Resources Limited has announced a $3.4 million capital raise through a flow-through share offer aimed at advancing exploration at its Portland Creek Uranium Project in Canada. The prospectus highlights significant risks but underscores the company's strategic focus on critical minerals.